Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 1, 2001, Pages 7-12

  Burman, W J ^a   Jones, B E ^a  

^a NONE   (United States)

Author keywords

Antiretroviral therapy; Drug drug interactions; HIV infection; Immune reconstitution; Protease inhibitor; Rifabutin; Rifampin; Tuberculosis

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; ISONIAZID; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RITONAVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; NOTE; PRIORITY JOURNAL; RASH; TUBERCULOSIS; VOMITING;

EID: 0035402130     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.1.2101133     Document Type: Note

References (50)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection
3. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
4. Tuberculosis in patients with acquired immunodeficiency syndrome: Clinical features, response to therapy, and survival
5. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire
6. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months
7. Low antituberculosis drug concentrations in patients with AIDS
8. Does AIDS impair the absorption of antituberculosis agents?
9. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection
10. Using therapeutic drug monitoring to dose the antimycobacterial drugs
11. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
12. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa
13. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis
14. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine, rifabutin
15. TBTC Study 22 (rifapentine trial): Preliminary results in HIV-negative patients
16. Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid
17. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events
18. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
19. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance
20. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
21. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
22. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis
23. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis
24. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin
25. Evaluation of an intensive intermittent-induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis
26. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in HIV patients
27. Pharmacokinetic interaction of nelfinavir with half-dose rifabutin
28. Treatment of tuberculosis in HIV-infected patients: Safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin
29. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study
30. Ritonavir enables combined therapy with rifampin and saquinavir
31. Pharmacokinetic interactions between lopinavir/ritonavir (ABT-378r) and other non-HIV drugs
32. Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection
33. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans
34. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months
35. Transitory exacerbation of fever and roentgenographic findings during treatment of tuberculosis in children
36. Paradoxical expansion of intracranial tuberculomas during chemotherapy
37. Paradoxical enlargement or development of intracranial tuberculomas during therapy: Case report and review
38. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
39. Immunopathology as a result of highly active antiretroviral therapy in HlV-1-infected patients
40. Immune mediated 'HAART' attack during treatment for tuberculosis
41. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy
42. Pulmonary tuberculosis in AIDS patients: Transient chest radiographic worsening after initiation of antiretroviral therapy
43. CNS manifestations of paradoxical reactions in HIV + TB patients on HAART
44. Tuberculosis reactivation in AIDS patients treated with highly active antiretroviral therapy
45. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis
46. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications
47. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients
48. Directly observed therapy of highly active antiretroviral therapy in patients with HIV and tuberculosis
49. Does tuberculosis treatment alter immunological and virological response to HAART?